These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 19176944)
1. Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Welin S; Stridsberg M; Cunningham J; Granberg D; Skogseid B; Oberg K; Eriksson B; Janson ET Neuroendocrinology; 2009; 89(3):302-7. PubMed ID: 19176944 [TBL] [Abstract][Full Text] [Related]
2. Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tumors. Namwongprom S; Wong FC; Tateishi U; Kim EE; Boonyaprapa S Ann Nucl Med; 2008 May; 22(4):237-43. PubMed ID: 18535873 [TBL] [Abstract][Full Text] [Related]
3. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues. Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194 [TBL] [Abstract][Full Text] [Related]
5. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors. Korse CM; Bonfrer JM; Aaronson NK; Hart AA; Taal BG Neuroendocrinology; 2009; 89(3):296-301. PubMed ID: 18840995 [TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radioligand uptake and tumor markers. Kälkner KM; Janson ET; Nilsson S; Carlsson S; Oberg K; Westlin JE Cancer Res; 1995 Dec; 55(23 Suppl):5801s-5804s. PubMed ID: 7493349 [TBL] [Abstract][Full Text] [Related]
7. Significance of plasma chromogranin A determination in neuroendocrine tumour (NET) diagnosis. Donica H; Malecha-Jędraszek A; Strosławska E; Burska A; Szubstarski F Folia Histochem Cytobiol; 2010 Dec; 48(4):603-10. PubMed ID: 21478104 [TBL] [Abstract][Full Text] [Related]
8. Prognostic clinicopathologic factors in longitudinally followed patients with metastatic small bowel carcinoid tumors. Curran T; Tulin-Silver S; Patel K; Ward S; Schneiderman M; Harpaz N; Schwartz M; Itzkowitz S; Warner RR; Kim MK Pancreas; 2011 Nov; 40(8):1253-7. PubMed ID: 21975435 [TBL] [Abstract][Full Text] [Related]
9. Description of patients with midgut carcinoid tumours: clinical database from a Danish centre. Nykjaer KM; Grønbaek H; Nielsen DT; Christiansen P; Astrup LB In Vivo; 2007; 21(4):679-84. PubMed ID: 17708366 [TBL] [Abstract][Full Text] [Related]
10. [The diagnostic value of plasma chromogranin A in neuroendocrine tumors]. Yang XO; Li JN; Qian JM; Yang H; Chen Q; Lu L Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):124-7. PubMed ID: 21418832 [TBL] [Abstract][Full Text] [Related]
11. Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors. Jensen EH; Kvols L; McLoughlin JM; Lewis JM; Alvarado MD; Yeatman T; Malafa M; Shibata D Ann Surg Oncol; 2007 Feb; 14(2):780-5. PubMed ID: 17146740 [TBL] [Abstract][Full Text] [Related]
12. Q RT-PCR detection of chromogranin A: a new standard in the identification of neuroendocrine tumor disease. Kidd M; Modlin IM; Mane SM; Camp RL; Shapiro MD Ann Surg; 2006 Feb; 243(2):273-80. PubMed ID: 16432362 [TBL] [Abstract][Full Text] [Related]
13. [Somatostatin receptor scintigraphy in preoperative diagnosis of the site of endocrine gastrointestinal tumors]. Weinel RJ; Kisker O; Joseph K; Welcke U; Zaraca F; Rothmund M Chirurg; 1994 Oct; 65(10):849-55. PubMed ID: 7821043 [TBL] [Abstract][Full Text] [Related]
14. Increase of urinary 5-hydroxyindoleacetic acid excretion but not serum chromogranin A following over-the-counter 5-hydroxytryptophan intake. Joy T; Walsh G; Tokmakejian S; Van Uum SH Can J Gastroenterol; 2008 Jan; 22(1):49-53. PubMed ID: 18209781 [TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal carcinoids: the evolution of diagnostic strategies. Modlin IM; Latich I; Zikusoka M; Kidd M; Eick G; Chan AK J Clin Gastroenterol; 2006 Aug; 40(7):572-82. PubMed ID: 16917396 [TBL] [Abstract][Full Text] [Related]
17. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution. Massironi S; Rossi RE; Casazza G; Conte D; Ciafardini C; Galeazzi M; Peracchi M Neuroendocrinology; 2014; 100(2-3):240-9. PubMed ID: 25428270 [TBL] [Abstract][Full Text] [Related]
19. Carcinoid syndrome: diagnosis and medical management. van der Lely AJ; de Herder WW Arq Bras Endocrinol Metabol; 2005 Oct; 49(5):850-60. PubMed ID: 16444370 [TBL] [Abstract][Full Text] [Related]
20. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors. Shanahan MA; Salem A; Fisher A; Cho CS; Leverson G; Winslow ER; Weber SM J Surg Res; 2016 Mar; 201(1):38-43. PubMed ID: 26850182 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]